Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology
A startup in the bustling Boston-area biotech hub hopes its new technology has solved a time-consuming aspect of developing drugs that rely on cell therapy: having to remove stem cells by hand, individually, during the manufacturing process.
Cellino, a regenerative medicine company, announced Monday that it concluded a $16 million seed financing round that will further advance technology that uses artificial intelligence and a personalized tissue and cell platform and ultimately seeks to generate autologous induced pluripotent stem cells at scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.